LENZ Therapeutics (LENZ) Non-Current Assets (2020 - 2026)
LENZ Therapeutics (LENZ) posted quarterly Non-Current Assets of $4.2 million for Q1 2026, up 22.84% year-over-year from $3.4 million in Q1 2025, and down 6.63% quarter-over-quarter from $4.5 million in Q4 2025.
LENZ Therapeutics (LENZ) Non-Current Assets (2020 - 2026) Analysis & Trends
LENZ Therapeutics (LENZ) has reported Non-Current Assets for 7 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 22.84% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $16.1 million (up 20.17% YoY), while the FY2025 annual figure was $4.5 million, up 31.8% from the prior year.
- Non-Current Assets fell to $4.2 million in Q1 2026 per LENZ's latest filing, from $4.5 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $46.5 million in Q4 2022 and bottomed at $648000.0 in Q1 2024.
- Historically, Non-Current Assets has averaged $16.5 million across 5 years, with a median of $4.2 million in 2026.
- Annual changes were most pronounced in 2022 — Non-Current Assets surged 1053.02% — and 2024, when it slumped 98.37%.
- LENZ Therapeutics' Non-Current Assets stood at $46.5 million in 2022, then plunged by 93.27% to $3.1 million in 2023, then gained by 8.14% to $3.4 million in 2024, then jumped by 31.8% to $4.5 million in 2025, then retreated by 6.63% to $4.2 million in 2026.
- Business Quant data shows LENZ's Non-Current Assets at $4.2 million in Q1 2026, $4.5 million in Q4 2025, and $3.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | LENZ Therapeutics | 147.30 Mn | 147.30 Mn | 5.21 Mn | 3.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.31 Mn |
| Mar 31, 2026 | 4.17 Mn |
| Dec 31, 2025 | 4.46 Mn |
| Sep 30, 2025 | 3.71 Mn |
| Jun 30, 2025 | 3.73 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.30 Mn |
| Jun 30, 2024 | 3.29 Mn |
| Mar 31, 2024 | 648,000.00 |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 27.45 Mn |
| Jun 30, 2023 | 35.87 Mn |
| Mar 31, 2023 | 39.69 Mn |
| Dec 31, 2022 | 46.54 Mn |
| Sep 30, 2022 | 36.35 Mn |
| Jun 30, 2022 | 27.14 Mn |
| Mar 31, 2022 | 34.85 Mn |
| Dec 31, 2021 | 20.25 Mn |
| Sep 30, 2021 | 14.92 Mn |